A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: October 15, 2008
Last updated: October 7, 2013
Last verified: October 2013
This 2 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo, both in combination with DMARDs, in patients with active rheumatoid arthritis who currently have an inadequate response to DMARD therapy. Patients will be randomized 2:1 to receive tocilizumab 8mg/kg iv or placebo iv every 4 weeks, in conjunction with stable DMARD therapy. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Condition Intervention Phase
Rheumatoid Arthritis
Drug: tocilizumab [RoActemra/Actemra]
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With DMARD Therapy, in Patients With Active Rheumatoid Arthritis and Inadequate Response to Current DMARD Therapy

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Proportion of patients with ACR20 response [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of patients with ACR50 and ACR70 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in individual parameters of ACR core set [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in a) HAQ-DI, b) FACIT fatigue score, c) rheumatoid factor, d) hemoglobin [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Time to onset of ACR20, 50 and 70 [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Proportion of patients achieving a) DAS28 <3.2 and b) DAS28 <2.6 [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 209
Study Start Date: October 2008
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: tocilizumab [RoActemra/Actemra]
8mg/kg iv every 4 weeks for 24 weeks
Placebo Comparator: 2 Drug: Placebo
iv every 4 weeks for 24 weeks


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, 18-70 years of age;
  • rheumatoid arthritis for >= 6 months;
  • receiving permitted DMARDs, at a stable dose, for >= 8 weeks prior to baseline;
  • current inadequate clinical response to DMARDs.

Exclusion Criteria:

  • major surgery, including joint surgery, within 8 weeks before entering study, or planned major surgery within 6 months following randomization;
  • rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis;
  • unsuccessful treatment with an anti-TNF agent;
  • previous treatment with tocilizumab.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00773461

Beijing, China, 100853
Beijing, China, 100044
Beijing, China, 100032
Guangzhou, China, 510630
Harbin, China, 150001
Jinan, China, 250012
Shanghai, China, 200001
Shanghai, China, 200433
Xi'an, China, 710032
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00773461     History of Changes
Other Study ID Numbers: ML21753 
Study First Received: October 15, 2008
Last Updated: October 7, 2013
Health Authority: China: Ministry of Health

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on April 27, 2016